… This study assessed the safety and efficacy of anlotinib as a third-line treatment or beyond
for patients with refractory advanced NSCLC. The results showed that the PFS, as well as the …

… data, we analysed the efficacy and safety of anlotinib combined with immunotherapy in the
treatment of third-line NSCLC, in order to guide future clinicians in applying this treatment. …

… anlotinib treatment as a third line and 27 patients received further … anlotinib is an effective
regimen for third-line or more-line treatment of advanced lung cancer and tolerance to anlotinib …

… -line) and our cohort (third line) were part of the reason for the prolonged OS, meanwhile, in
standard third line treatment, anlotinib … survival time compared with chemotherapy. Besides, …

… the efficacy and safety of anlotinib as a third-line and subsequent treatment for patients
with … The reported OS with cytotoxic treatment as the third line was 4.4–5.8 months, 17,19,21,22 …

… Consequently, the present study was to investigate the efficacy and safety of anlotinib in
third-line therapy for elderly patients with advanced NSCLC and the clinical significance …

… , chemotherapy plus anlotinib combined with anlotinib maintenance may be a reliable, safe
and feasible treatment … -line treatment. Based on clinical evidence supporting the use of …

… Here, we evaluated the efficacy and safety of anlotinib as third-line treatment for advanced …
after at least 2 lines of prior therapies were randomized 2:1 to receive anlotinib or placebo (12 …

… of anlotinib inhibiting tumor angiogenesis is that anlotinib … the efficacy and safety of third‑line
treatment with anlotinib for … The anlotinib treatment group was indicated to be better than …

… patients who received anlotinib monotherapy as third-line or later-line treatment in Shandong
… study indicated that anlotinib seemed to be safe for later-line treatment in refractory SCLC. …